<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198103</url>
  </required_header>
  <id_info>
    <org_study_id>RS.99</org_study_id>
    <nct_id>NCT04198103</nct_id>
  </id_info>
  <brief_title>Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia</brief_title>
  <official_title>Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia: A Feasibility Study - Results at 6 and 12 Months From a Retrospective Multi-centric Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ospedale Regina Apostolorum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rome Tor Vergata</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigated the effectiveness and safety of SoracteLite ™- Trans-Perineal Laser
      ablation (TPLA) in the treatment of patients with symptomatic Benign Prostatic Hyperplasia
      (BPH) at 6 and 12 months follow-up
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to investigate the effectiveness and safety of SoracteLite ™ -
      Trans-Perineal Laser ablation (TPLA) in the treatment of patients with symptomatic benign
      prostatic hyperplasia (BPH) at 6 and 12 months follow-up. Methods: Patients with urinary
      symptoms secondary to BPH underwent TPLA under local anaesthesia in four centers. Under US
      guidance, up to four 21G applicators were inserted in the prostatic tissue. Each treatment
      was performed with diode laser operating at 1064 nm changing the illumination time according
      to prostate size.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical symptoms changes at 6 months and 12 months follow-up evaluated with objective and subjective parameters</measure>
    <time_frame>12 months</time_frame>
    <description>Improvement of obstructive symptomatology correlated to BPH. The evaluation will be based on urodynamic studies of Qmax, post void and residual volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment safety measured by complications incidence</measure>
    <time_frame>30 days</time_frame>
    <description>Number of incidence of Complication according to modified Clavien classification system</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>BPH</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>SoracteLite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transperineal Focal Laser Ablation (TPLA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transperineal Focal Laser Ablation (TPLA)</intervention_name>
    <description>The intervention will take place in an ambulatory setting using EchoLaser system. The treatment consists of the trasmission of laser energy into the tissue through the percutaneous insertion of optical fiber under local anesthesia. Within each needle, an optic fiber of 300 µm will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 3W. At the end of the first ablation there is a pull-back of about 1 cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used for a total duration of about 30minutes. At the end of the treatment corticosteroid is given for anti-edema and anti-inflammatory effects and Antibiotic therapy and gastroprotective therapy is given. After an adequate amount of time for observation, the patient is dismissed.</description>
    <arm_group_label>SoracteLite</arm_group_label>
    <other_name>SoracteLite EchoLaser</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  ≥ 50 years of age

          -  International Prostate Symptoms (IPSS) ≥12

          -  Peak urinary flow rate (Qmax): &lt;15 ml

          -  Prostate volume: ≥ 30 ml, measured by transrectal ultrasound

          -  Post-void residual (PVR): &lt;400 ml

          -  Signed informed consent

        Exclusion Criteria:

          -  MRI signs of malignancy confirmed by biopsy investigation

          -  urethral stenosis

          -  serious coagulation disorders

          -  inadequate compliance

          -  ischemic pathology in the previous six months

          -  active phase inflammatory pathology
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Casa di Cura Santa Rita</name>
      <address>
        <city>Atripalda</city>
        <state>AV</state>
        <zip>83042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Bergamo Est</name>
      <address>
        <city>Seriate</city>
        <state>BG</state>
        <zip>24068</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Tor Vergata (PTV) Foundation: UOC Department of Diagnostic Imaging and Interventional Radiology</name>
      <address>
        <city>Rome</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IGreco Ospedali Riuniti</name>
      <address>
        <city>Cosenza</city>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Patelli G, Ranieri A, Paganelli A, Mauri G, Pacella CM. Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia: A Feasibility Study. Cardiovasc Intervent Radiol. 2017 Sep;40(9):1440-1446. doi: 10.1007/s00270-017-1662-9. Epub 2017 May 4.</citation>
    <PMID>28474112</PMID>
  </reference>
  <reference>
    <citation>Raz O, Haider MA, Davidson SR, Lindner U, Hlasny E, Weersink R, Gertner MR, Kucharczyk W, McCluskey SA, Trachtenberg J. Real-time magnetic resonance imaging-guided focal laser therapy in patients with low-risk prostate cancer. Eur Urol. 2010 Jul;58(1):173-7. doi: 10.1016/j.eururo.2010.03.006. Epub 2010 Mar 12. Erratum in: Eur Urol. 2010 Sep;58(3):473. Kucharcyzk, Walter [corrected to Kucharczyk, Walter].</citation>
    <PMID>20334965</PMID>
  </reference>
  <reference>
    <citation>Lindner U, Weersink RA, Haider MA, Gertner MR, Davidson SR, Atri M, Wilson BC, Fenster A, Trachtenberg J. Image guided photothermal focal therapy for localized prostate cancer: phase I trial. J Urol. 2009 Oct;182(4):1371-7. doi: 10.1016/j.juro.2009.06.035. Epub 2009 Aug 14.</citation>
    <PMID>19683262</PMID>
  </reference>
  <reference>
    <citation>Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD 3rd, Dupuy DE, Gervais D, Gillams AR, Kane RA, Lee FT Jr, Livraghi T, McGahan J, Phillips DA, Rhim H, Silverman SG; Society of Interventional Radiology Technology Assessment Committee. Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2005 Jun;16(6):765-78.</citation>
    <PMID>15947040</PMID>
  </reference>
  <reference>
    <citation>Bremer C, Kreft G, Roggan A, Filler T, Reimer P. Ex vivo evaluation of novel miniaturized laser-induced interstitial thermotherapy applicators for effective small-volume tissue ablation. Invest Radiol. 2001 Jun;36(6):327-34.</citation>
    <PMID>11410753</PMID>
  </reference>
  <reference>
    <citation>Costello AJ, Bowsher WG, Bolton DM, Braslis KG, Burt J. Laser ablation of the prostate in patients with benign prostatic hypertrophy. Br J Urol. 1992 Jun;69(6):603-8.</citation>
    <PMID>1379101</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 8, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rome Tor Vergata</investigator_affiliation>
    <investigator_full_name>Guglielmo Manenti</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>BPH</keyword>
  <keyword>LUTS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

